FAXELADOL HYDROCHLORIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C15H23NO.ClH
Molecular Weight	269.81
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CN(C)C[C@@H]1CCCC[C@H]1C2=CC(O)=CC=C2

InChI

InChIKey=SLOIWIHZXQWWIY-SLHAJLBXSA-N

InChI=1S/C15H23NO.ClH/c1-16(2)11-13-6-3-4-9-15(13)12-7-5-8-14(17)10-12;/h5,7-8,10,13,15,17H,3-4,6,9,11H2,1-2H3;1H/t13-,15-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	C15H23NO
Molecular Weight	233.3492
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22337471 | https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001404-40/DK | https://adisinsight.springer.com/drugs/800032836

Faxeladol (GRT9906) is a μ-opioid receptor agonist and inhibitor of noradrenalin/serotonin re-uptake. Faxeladol was being studied in the treatment of fibromyalgia and neuropathic pain, however its development has been discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed
Randomized controlled trial of the combined monoaminergic and opioid investigational compound GRT9906 in painful polyneuropathy.	2012 Jul	22337471

Patents

Sample Use Guides

In Vivo Use Guide

During 4-week treatment periods, daily oral doses of faxeladol (GRT9906) 120-240 mg

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:35:42 UTC 2023` Edited by `admin` on `Fri Dec 15 15:35:42 UTC 2023`
Record UNII	7UJ3BJQ4P0
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FAXELADOL HYDROCHLORIDE

Common Name

English

FAXELADOL HCL

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C67413